digital currency market login Top People also ask

Ha Sanlian: Four kinds of drugs are planned to win the bid for national centralized procurement. Ha Sanlian announced that the company and its wholly-owned subsidiary Lanxi Pharmaceutical participated in the tenth batch of national centralized procurement of drugs organized by the state. The company's esmolol hydrochloride injection, pentoxifylline injection, potassium chloride injection, and tandospirone citrate tablets of Lanxi Pharmaceutical intend to win the bid for this centralized procurement. If the subsequent purchase contract is signed and implemented, it will help to expand the sales of related products and improve the market share and brand influence. The prices of the above-mentioned drugs are respectively 1.34 yuan for esmolol hydrochloride injection, 0.59 yuan for pentoxifylline injection, 0.16 yuan for potassium chloride injection and 6.56 yuan for tandospirone citrate tablets.Hengrui Pharma: SHR-2173 injection was approved for clinical trial. Hengrui Pharma announced that its subsidiary, Guangdong Hengrui Pharma Co., Ltd., received the Notice of Approval for Clinical Trial of SHR-2173 injection approved and issued by National Medical Products Administration, and agreed to carry out clinical trial. The indication is lupus nephritis. SHR-2173 injection is a therapeutic biological product independently developed by the company, and the research and development expenses have been invested about 45.03 million yuan. The period from research and development to listing of drugs is long, there are many links, and there are uncertain factors. The company will actively promote research and development projects and fulfill its information disclosure obligations.Hite Bio: Two drugs are planned to be selected for national centralized drug procurement. Hite Bio announced that the company participated in the tenth batch of national centralized drug procurement. According to the selected results released by the joint procurement, roxatidine acetate hydrochloride and pentoxifylline injection for injection of the company are selected for this centralized procurement. These two drugs are suitable for the treatment of upper gastrointestinal bleeding and peripheral arterial diseases respectively. The procurement cycle is from the date of implementation of the selected results to December 31, 2027, during which medical institutions will give priority to the use of selected drugs. The company obtained the Drug Registration Certificate of the above drugs in 2024, but it has not generated sales revenue this year. This election will help to enhance the brand influence of the company and have a positive impact on the company's development.

Shanghai Electric established a new company including machinery and equipment sales business. According to the enterprise search APP, Shanghai Dixi New Energy Co., Ltd. was established with Ye Can as its legal representative and registered capital of 1 million yuan. Its business scope includes: power generation business, power transmission business and power supply (distribution) business; Installation, maintenance and testing of power transmission, power supply and power reception facilities; Mechanical equipment sales; Mechanical and electrical equipment sales, etc. Enterprise survey shows that the company is wholly owned by Shanghai Electric New Energy Development Co., Ltd., a subsidiary of Shanghai Electric.During the policy landing period, the market may become a structural market, which is expected to further benefit the performance of high-interest stocks. On December 13, the Standard & Poor's dividend ETF(562060) closed down by 1.93%, with a turnover of 35.7287 million yuan. Puyin International pointed out that next year, before the two sessions next year, it will enter the policy landing period, and more detailed policies will be gradually implemented. The superimposed overseas uncertainty may increase with Trump's coming to power, so we expect the market to present a structural market. Based on the profit growth rate, capital stock, liquidity and market sentiment, the overall performance of A shares may be more stable than that of overseas Chinese shares. Investment trading strategy suggests both offensive and defensive. When the market sentiment improves and the stock index rebounds, it is expected that the high beta sector, such as non-bank finance, optional and mandatory consumption, real estate and other sectors and individual stocks may be more elastic. When the market sentiment is low and the stock index fluctuates downward, funds may prefer more defensive sectors, such as telecommunications services. There are many high-quality and high-interest stocks in the defensive sector. There is still room for the Bank of China to cut interest rates further next year, which is expected to further benefit the performance of high-interest stocks.Shanghai Gold Exchange: the settlement price of NYAuTN12 contract in Shanghai New Zealand was 627.85 yuan/gram. On December 13th, Shanghai Gold Exchange issued a notice saying that NYAuTN12 contract in Shanghai New Zealand was settled on December 13th, 2024. The details of the settlement of the contract are as follows: the settlement price of NYAuTN12 contract in Shanghai New Zealand was 627.85 yuan/gram.

Vegetable oil fell by 1.90% on the 13th, and the latest main contract positions changed as follows. According to the exchange data, as of December 13th, the main contract vegetable oil closed at 2,505, up or down by -1.90%, with a turnover of 535,800 lots. The position data showed that the top 20 seats were clear, and the difference position was 21,545 lots. The total turnover of vegetable oil futures contracts was 593,700 lots, a decrease of 112,100 lots from the previous day. The first 20 seats in the contract held 232,900 lots, a decrease of 3,819 lots from the previous day. The short positions in the top 20 seats of the contract were 254,200 lots, an increase of 687 lots over the previous day. (Sina Futures)AI glasses ushered in the limelight, and Google reached a cooperation with domestic manufacturers. According to the news, on December 13, at the Android XR conference, Google reached a strategic cooperation with domestic consumer-grade AR glasses manufacturer XREAL to jointly build the Android XR ecosystem. According to media reports, OPPO, vivo, Huawei, Tencent and ByteDance are all evaluating the AI glasses project. In addition, a number of listed companies said on the investor question and answer platform that they have corresponding technology or product reserves in AI glasses. Huaxin Securities Research Report pointed out that AI glasses have become a new outlet in the smart wear market, or lead the next generation of terminal revolution. AI glasses not only have the effect of virtual vision enhancement, but also realize real-time analysis of user behavior and environment by integrating artificial intelligence algorithms, providing more accurate and personalized services. AI glasses also improve comfort and prolong wearing time in design and portability. At the same time, it provides a more natural and convenient interactive experience innovation through various sensing technologies. With the gradual reduction of costs, AI glasses are expected to be further widely used. According to the report of Wellsenn XR, it is estimated that after 2030, the AI+AR smart glasses industry will enter a period of rapid development; By 2035, AI+AR smart glasses will eventually replace traditional smart glasses, and the global sales of AI+AR smart glasses will reach 1.4 billion units, which is equivalent to the size of smart phones and will become the next generation general computing platform and terminal. (Securities Times)Yingli shares: Yingli shares increased capital by 80 million yuan to its holding subsidiary. Yingli shares announced that the company and Shanghai Moqin Intelligent Technology Co., Ltd. increased capital to Nanchang Yingli Precision Manufacturing Co., Ltd., with a total capital increase of 80 million yuan, of which Yingli shares increased capital by 67 million yuan in cash and Shanghai Moqin increased capital by 13 million yuan in cash. After this capital increase, the registered capital of Nanchang Yingli will increase from 20 million yuan to 100 million yuan. After the capital increase is completed, Yingli shares hold 80% of the shares of Nanchang Yingli and Shanghai Moqin holds 20% of the shares. This capital increase does not constitute a connected transaction and does not need to be submitted to the company's shareholders' meeting for consideration.